Q4 2025 BioCardia Inc Earnings Call Transcript
Key Points
- BioCardia Inc (BCDA) has completed and presented final data from three clinical trials of their CardiAM therapy, showing promising results in treating ischemic heart failure.
- The CardiAM therapy has shown statistically significant improvements in heart function for patients with elevated biomarkers of heart stress, with p-values of 0.02 and 0.01.
- BioCardia Inc (BCDA) is actively engaging with the FDA and Japan's PMDA for potential approval of their therapies, indicating progress towards market entry.
- The company has initiated the CardiA HF2 confirmatory clinical study, focusing on patients who showed the greatest response in previous trials.
- BioCardia Inc (BCDA) has maintained a stable financial position with careful management of resources, ending the year with $2.5 million in cash and cash equivalents.
- The P values for the diastolic and systolic volumes in the complete population were not statistically significant, indicating room for improvement in overall efficacy.
- Research and development expenses increased by 13% in 2025, primarily due to trial closeout activities and regulatory efforts, which could strain financial resources.
- The company's net loss increased modestly to $8.2 million in 2025, reflecting ongoing financial challenges.
- Enrollment in the CardiA HF2 trial is progressing slowly, primarily due to resource constraints and focus on regulatory submissions.
- BioCardia Inc (BCDA) faces competition from other companies seeking approval for cell therapies for heart failure, which could impact market share and adoption.
Ladies and gentlemen, thank you for standing by. Good afternoon and welcome to the BioCardia year-end 2025 financial results and business update conference call. (Operator Instructions)
Participants of this call are advised that the audio of this conference call is being broadcast live over the internet and is also being recorded for playback purposes. A webcast replay of the call will be available approximately one hour after the end of the call.
I would now like to turn the conference over to Miranda Peto of BioCardia Investor Relations. Please go ahead, Miranda.
Good afternoon and thank you for participating in today's conference call. Joining me from Biocardia's leadership team are Peter Altman, President and Chief Executive Officer, and David McClung, the company's Chief Financial Officer. During this call, management will be making forward-looking statements, including statements that address biocaria's expectations for future performance and operational results, references to management
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
